Division of Hematologic Malignancies & Hematopoietic Stem Cell Transplantation
Leadership
- Director, Division of Hematologic Malignancies & Cellular Therapy
- Program Leader, Immune Cell Regulation & Targeting (IRT)
- Co-Director, Blood Cancer Center of Excellence (BCCE)
- Professor of Medical Oncology; Dermatology, & Cutaneous Biology
834 Chestnut Street
Suite 320
Philadelphia, PA 19107
For Patient Inquiries
New Patients: 1-800-JEFF-NOW
Existing Patients: 215-955-8874
The Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation is composed of 12 physicians with subspecialty oncology experience in specific hematologic malignancies and palliative care, which provides clinical expertise and research opportunities for leukemias and MDS, lymphomas, myeloma, and bone marrow transplantation related to these conditions.
Partnered Programs
Blood & Marrow Transplantation Program
Since its inception, Jefferson’s Bone Marrow Transplant Program (BMT) has completed more than 1,000 bone marrow transplants, with increasingly impressive outcomes. These include the region’s highest actual one-year patient survival rates, according to National Marrow Donor Program Center Specific analyses for 2013 and 2014. The transplant program now has an international reputation for its unique approach to haplo-identical transplants. Drs. Flomenberg, Grosso, Carabasi, Wagner, and Filicko-O’Hara all play important roles in the transplant effort.
In an October 2014 article published in the Biology of Blood and Marrow Transplantation, Jefferson reported “disease-free and overall survival at 2 years are 74% and 77%, respectively, consistent with the findings (of previous work) and supporting the use of this approach in earlier stage patients lacking a matched related donor.”
In the BBMT’s editorial commentary, Dr. Andrea Veraldi provided praise to the Jefferson’s report, noting:
"These outcomes are extremely encouraging… All the recent reports of unmanipulated haploidentical transplantation have fostered interest and debate in the field and, most importantly, served to substantially extend its use. The new 2-step approach, as adopted by (Jefferson’s BMT Program), provides very interesting results. It is to be hoped they will be confirmed in a longer follow-up and a larger cohort of patients."
The BMT program will to conduct clinical research on the potential benefit of the two-step haplo-identical transplant approach.
Department of Medicine, Division of Hematology
The Division of Hematology supports Jefferson’s efforts in hemostasis/thrombosis, hemoglobinopathies, and other aspects of non-malignant hematology. The division of hematology co-directs the joint Hematology/Medical Oncology Fellowship Program with the Department of Medical Oncology and its hematologists frequently collaborate with the Division of Medical Oncology in both clinical and investigational activities. The Division of Hematology faculty are principally devoted to research into the causes of a wide variety of diseases of the blood and to the diagnosis and care of patients with blood and lymphatic diseases. They have competence in all areas of hematology, with particularly well-recognized depth and experience in:
- Diseases affecting blood platelets
- Hemorrhagic (bleeding) and thrombotic (clotting) disorders
- Other bone marrow disorders
Cardeza Foundation for Hematologic Research
The Cardeza Foundation for Hematologic Research was founded in 1941 by Mr. and Mrs. Thomas D. Cardeza as a memorial to Mr. Cardeza's mother, Charlotte Drake Cardeza. Since then, members of the Cardeza Foundation and Jefferson's Division of Hematology have been devoted to research into the causes of a wide variety of diseases of the blood and have initiated and participated in a number of clinical trials of newer types of therapy for many of these disorders. Currently, the Cardeza Foundation supports faculty salaries, research programs and education programs within the Division of Hematology.